*Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

†Delphi Diagnostics, Baltimore, MD

Supported by the Memorial Sloan Kettering Cancer Center Support Grant P30 CA008748, NCI. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

P.B.B. reports employment at Delphi Diagnostics, personal fees from Mercer, personal fees and nonfinancial support from United Rheumatology, personal fees from Foundation Medicine, personal fees from Grail, personal fees from Morgan Stanley, personal fees from NYS Rheumatology Society, personal fees and nonfinancial support from Oppenheimer & Co, personal fees from Cello Health, personal fees, nonfinancial support and other from Oncology Analytics, personal fees from Anthem, personal fees from Magellan Health, personal fees and nonfinancial support from Kaiser Permanente Institute for Health Policy, personal fees and nonfinancial support from Congressional Budget Office, personal fees and nonfinancial support from America’s Health Insurance Plans, grants from Kaiser Permanente, grants from Arnold Ventures, personal fees and nonfinancial support from Geisinger, personal fees from EQRx, personal fees from Meyer Cancer Center of Weill Cornell Medicine, and personal fees from National Pharmaceutical Council. The remaining authors declare no conflict of interest.

Correspondence to: Aaron P. Mitchell, MD, MPH, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY 10017. E-mail: [email protected].